Recently, BridgeBio Pharma announced that its investigational treatment, acaracides, achieved its primary endpoint in the phase 3 clinical trial.

On August 29, 2023, Novartis released new long-term data from its ORION-8 Phase 3 clinical trial. The data showed that its twice-yearly RNAi therapy, Leqvio (Inclisiran, Sodium Echociliran), in combination with statins.

On August 29, 2023, AbbVie submitted a new indication application to the US FDA and European EMA for Skyrizi (Risankizumab) for the treatment of moderate to severe ulcerative colitis (UC) in adults.

Merck announced that Merck announced that the European Commission has approved KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-positive gastric or gastroesophageal junction adenocarcinoma in adults whose tumors express PD-L1 (Combined Positive Score≥1).

AEON Biopharma, Inc. has shared encouraging results from their recent Phase 2 medical trial of ABP-450.

TScan Therapeutics, Inc.announced today that the U.S. FDA has given approval for its new experimental drug TSC-203-A0201, a TCR-T pinpointing PReferentially expressed Antigen in Melanoma.

SparingVision has shared encouraging early safety data from the Phase I/II clinical trial of its primary gene-agnostic gene therapy, SPVN06, designed to treat retinitis pigmentosa.

Janssen has filed an additional Biologics License Application with the U.S. Food and Drug Administration, seeking endorsement for RYBREVANT® (amivantamab-vmjw) to be combined with Chemotherapy.

Tourmaline Bio reported that the FDA has conditionally approved the Investigational New Drug (IND) application for TOUR006.

The inaugural patient has been administered with ATSN-201 under the Phase I/II Clinical Trial, for combatting X-linked Retinoschisis, as announced by Atsena Therapeutics.

The U.S. FDA has sanctioned the use of Bristol Myers Squibb's Reblozyl® (luspatercept-aamt) as an initial treatment option for anemia in adults suffering from low-risk Myelodysplastic Syndromes (MDS) who might need transfusions.

Formycon has publicized that its biosimilar candidate FYB203, a potential replica of Eylea® (aflibercept), has been approved for filing by the U.S. Food and Drug Administration (FDA).